Status:
COMPLETED
A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment
Lead Sponsor:
Melbourne Health
Collaborating Sponsors:
Stanley Medical Research Institute
Southern Health
Conditions:
Psychotic Disorders
Eligibility:
All Genders
18-25 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine whether Taurine 4g is effective with antipsychotic medication in the treatment of First Episode Psychosis.Taurine may have an effect on cognition and symptoms...
Detailed Description
The core rationale of this study will be to prospectively investigate whether Taurine will improve and /or protect cognitive functioning and improve symptomatology in a cohort of 128 first episode psy...
Eligibility Criteria
Inclusion
- Male and females
- Between 18 and 25 years of age
- First Episode Psychosis
- Attending ORYGEN Youth Health, a geographical based catchment area service for young people aged between 15 and 25.
Exclusion
- Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal lobe epilepsy, HIV encephalopathy)
- Mental retardation (unable and/or unlikely to give appropriate information of symptomatology or side-effects (IQ approximately lower than 80)
- History of clinically significant physical illness (e.g. terminal cancer, renal dialysis)
- History of brain surgery
- History of brain infarction
- Pregnant or lactating women or women of childbearing potential not using an acceptable method of contraception.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00420823
Start Date
January 1 2007
End Date
December 1 2010
Last Update
November 20 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
ORYGEN Youth Health
Melbourne, Victoria, Australia, 3052
2
RAPPS programme, Southern Health
Melbourne, Victoria, Australia, 3168